Answers are grounded in this paper and cite their sources.
Preliminary findings demonstrate daptomycin achieves effective concentrations in cerebrospinal fluid, indicating potential treatment benefits for pneumococcal meningitis.
We conclude that daptomycin administered at a dose of 10 mg/kg/day achieves CSF concentrations that may exert non-lytic anti-pneumococcal effects and demonstrate significant activity against highly resistant pneumococcal strains. These findings suggest that daptomycin could be considered as a valuable adjunctive therapy in the treatment of pneumococcal meningitis.
No takes yet. Share an insight, caveat, or question.
Tetu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: